Introduction
A large body of evidence supports the relation of excess sodium intake with higher blood pressure 1, 2 and risk of stroke. 3 Its association with coronary heart disease (CHD), however, is much less well-established. Whereas many studies primarily addressed the association between sodium intake and heterogeneous cardiovascular outcomes, 3 studies specifically 4 or additionally [5] [6] [7] [8] [9] [10] [11] [12] [13] addressing CHD are relatively sparse with conflicting results varying from positive, 5, 7, 10, 13 to no, 6, 9, 11 or inverse associations. 4, 8, 12 Part of the discrepancies may be due to the use of suboptimal measures of sodium intake, such as dietary recall or spot urine, and only few prospective studies had the advantage of repeated 24h urine collections. 7, 10 Considerable between-individual differences are present in the body's susceptibility to altered sodium intake, that moreover, have been related to long term outcome. 14 Such differences can be clinically apparent from the responses of blood pressure to altered sodium intake, 15, 16 but also from differences in the responses of the extracellular volume, in the absence of effects on blood pressure. 17 Both increased blood pressure, and higher levels of volume markers (i.e. Nterminal pro-B-Type natriuretic peptide (NT-proBNP) and N-terminal atrial natriuretic peptide) have been identified as conditions with enhanced susceptibility to changes in sodium intake. 18, 19 Whether increased blood pressure and/or elevated volume markers could identify individuals susceptible to the effects of excess sodium intake on risk of CHD has not been investigated so far.
Therefore, the aim of our study was to examine the association between sodium intake, assessed from repeated 24h urine collections, and risk of CHD in the general population and in subgroups potentially more sensitive to the effects of sodium intake, i.e. subjects with higher blood pressure or with increased circulating NT-proBNP concentrations.
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Methods

Study Design and Population
We followed participants in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study. The PREVEND study is designed to prospectively investigate the natural course of albuminuria and its relation to renal and cardiovascular disease in a large cohort drawn from the general population. Details of this study have been described elsewhere. 20 In brief, from 1997 to 1998, all inhabitants of Groningen, the Netherlands aged 28-75 years, were sent a questionnaire and a vial to collect a first morning void urine sample. Pregnant women and subjects with type 1 diabetes mellitus were excluded. Urinary albumin concentration was assessed in 40,856 responders. Subjects with a urinary albumin concentration of 10 mg/L (n=7768) were invited to participate, of whom 6000 were enrolled. In addition, a randomly selected group with a urinary albumin concentration of <10 mg/L (n=3394) was invited to participate in the cohort, of whom 2592 were enrolled. These 8592 individuals form the PREVEND cohort.
For the present study, we excluded subjects with a history of cardiovascular disease (n=451), kidney disease requiring dialysis (n=18) or malignancies (n=124) at baseline. We also excluded subjects with missing baseline data on urine (n=91) and serum (n=220) measurements, or questionnaire data (n=145), leaving 7543 subjects for the analysis. The PREVEND study has been approved by the medical ethics committee of the University Medical Center Groningen and is conducted in accordance with the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all participants.
Data Collection
Participants underwent two visits to the outpatient research unit for the baseline examination. At Information on hospitalization for cardiac morbidity was obtained from PRISMANT, the Dutch national registry of hospital discharge diagnoses and was previously validated. 25 Data were coded according to the International Classification of Diseases, 9 th revision and the classification of interventions. For our study, CHD was defined as myocardial infarction (ICD-code 410), acute and subacute ischemic heart disease (ICD-code 411), and coronary artery bypass grafting or percutaneous transluminal coronary angioplasty.
Statistical Analysis
The urinary sodium concentration was multiplied by urine volume to obtain a value in mmol per 24h. To assess the within-subject correlation between the repeated 24h urinary sodium excretions, we calculated the Pearson product-moment correlation coefficient. Since the withinsubject sodium excretions were highly correlated (r=0.59; P<0.0001), the two sodium values of each subject were averaged. Baseline characteristics are presented according to sex-specific quartiles of 24h urinary sodium excretion.
Timed 24h urinary sodium excretion, considered the "gold standard" method to estimate nformation on hospitalization for cardiac morbidity was obtained from PRISMA MA ANT NT T, th th he e e Du Du Dutc tch national registry of hospital discharge diagnoses and was previously validated. 25 Data were smoking status (never, former, current <6 cigarettes/day, current 6-20 cigarettes/day or current >20 cigarettes/day), alcohol consumption (five categories), family history of CHD, presence of type 2 diabetes, total to HDL cholesterol ratio and urinary magnesium, potassium, and creatinine excretion. By controlling for urine creatinine we adjusted indirectly for both muscle mass and body dimension. All models took into account the sampling design of the study (presence or absence of albuminuria >10 mg/L) by specifying stratum-specific baseline hazard functions. If
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Effect modification of the association between sodium excretion and CHD risk by blood pressure and NT-proBNP was assessed by a likelihood ratio test of the cross-product terms in multivariable models that also included main-effect terms of sodium excretion and blood pressure or NT-proBNP. We fit both blood pressure and NT-proBNP as quadratic splines with two knots to optimize model fit. We used mean arterial pressure (MAP; defined as: [ and untreated hypertensive subjects in our study and correspond with reductions in blood pressure after antihypertensive interventions. 27, 28 In sensitivity analyses, we excluded 24h urine samples with possible over or under collections. Such samples were defined as the upper and lower 2.5% of the difference between the estimated and measured volume of a subject's 24h urine sample. The estimated 24h urine volume was derived from the formula: Creatinine clearance = ([Urine creatinine] * 24h urine volume) / [Serum creatinine]), where creatinine clearance was estimated using the CockcroftGault formula. 29 To address potential reverse causation, we also repeated the analyses excluding subjects with incident CHD in the first two years of follow-up. Since urinary albumin excretion may be an effect modifier in the association between sodium excretion and CHD risk, we restricted the cohort to the subjects with an albuminuria concentration of 10 mg/L. In secondary analyses, we used a less conservative and broader but more general definition for CHD by medication use, we added 10 mm Hg to the SBP and 5 mm Hg to the DBP of tre ea a ated ed ed hypertensive participants. These values are the difference in mean SBP and DBP between treated an nd d d un un untr tr trea ea ate te ted d d hy y ype pe pert r ensive subjects in our study y y an an a d d correspond w w with h r r red ed educ u tions in blood pres s ssu s re after a ant n ntih h hyp ype erte te tens ns nsiv iv ve e e in inte te ter rv rve en nt tions s s.
additionally including old myocardial infarction (ICD-code 412), angina pectoris (ICD-code 413), and other forms of chronic ischemic heart disease (ICD-code 414) in our initial definition.
Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS Inc, Chicago, IL), version 20.0 and SAS (SAS Institute, Cary, NC), version 9.3. We did not adjust for multiple comparisons. Because of the general low power for interaction tests, interaction terms were considered to be statistically significant at two-sided P-values <0.10, as recommended by Selvin 30 and by the Food and Drug Administration authorities. 31 Otherwise, two-sided P-values <0.05 were considered statistically significant.
Results
The median 24h sodium excretion was 137 mmol (Q1-Q3: 106-171 mmol), which corresponds to a daily intake of 8.4 g of sodium chloride after accounting for non-urinary loss. The mean 24h sodium excretion was 142 mmol (standard deviation: 51 mmol). Baseline characteristics of the cohort are presented in sex-specific quartiles of sodium excretion in Table 1 . At baseline, a higher sodium excretion was univariately associated with lower age, higher BMI, lower NTproBNP, higher eGFR and higher urine levels of potassium, magnesium, creatinine, and albumin. In univariate models, SBP and DBP, hypertensive medication use and parental history of CHD were not associated with baseline sodium excretion.
The study had a median follow-up of 10.5 years (Q1-Q3: 9.9-10.8 years; 71,491 personyears) in which 452 incident cases of CHD occurred. Events included 188 cases of myocardial infarction (of which 22 were fatal), 134 hospitalizations for ischemic heart disease (of which 16
were fatal), and 130 revascularizations. In the entire cohort, there was no significant association (P=0.15) between a continuous term of sodium excretion and risk of CHD after multivariable
The median 24h sodium excretion was 137 mmol (Q1-Q3: 106-171 mmol), which corresponds to a da da ail il ily y y i in inta ta take ke ke of f 8 8. higher sodiu um m m ex ex e cr cr cret et e io io on n n wa wa was s s un un niv iv iva ari ri riat atel el ely y y as as sso so oci ci c at at a ed ed ed w wit it th h h lo lo lowe we wer r r ag ag a e, e, e, h h hig ig ighe he her r r BM BM MI, I, I, l l low ow ower NT-adjustment ( Table 2) . No significant deviations from linearity were detected for this association (P nonlinearity =0.79). The restricted multivariable-adjusted spline plot is presented in Figure 1 . We also considered a cut point of more extreme sodium excretion. The HRs for the upper two deciles of the distribution of sodium excretion as compared to the lowest half of the distribution were 1.24 (95% CI, 0.88-1.73) and 1.27 (95% CI, 0.89-1.81) respectively, consistent with no significant deviation from linearity and absence of an association at the extreme ends of the distribution.
The association of sodium excretion with CHD risk tended to be modified by MAP (P interaction =0.08) and was modified by NT-proBNP (P interaction =0.002). For clinical relevance and ease of interpretation, we stratified the association by hypertension status and by NT-proBNP concentration above the sex-specific median (22 pg/mL for men; 50 pg/mL for women),
respectively. In these stratified analyses, we observed reversed trends across the two strata of hypertension status and NTproBNP status. The associations between sodium excretion and risk of CHD were significant only among subjects with hypertension (HR, 1.14; 95% CI, 1.01-1.28)
or with a NT-proBNP concentration above the sex-specific median (HR, 1.16; 95% CI, 1.03-1.30) ( Table 3) for each 1-g/d increment. Results remained materially unchanged when the cohort was stratified by MAP in groups with similar sizes as those of the normotensive and hypertensive strata. In these analyses, the HRs associated with 1-g/d increment in sodium excretion were 0.96 (95% CI, 0.81-1.14; N=5178) for subjects with a MAP <98 mm Hg and 1.14 (95% CI, 1.01-1.28; N=2365) for subjects with a MAP 98 mm Hg.
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or with a NT T-p -p pro ro r BN BN BNP P co co onc c cen en entr trat at atio io i n n n ab ab bov ov ove e e th th the e e se se sex-x-x sp sp spec ec cif if ific ic c m m med ed edia ia i n n n (H (H (HR, R, R, 1 1 1.1 .1 .16; 6; ; 9 9 95% 5% 5% C C CI, 1.03-hypertension. To formally test whether the effect modification by NT-proBNP was independent of blood pressure, we simultaneously included main-effects for sodium excretion, and spline functions of NT-proBNP and MAP and both cross-product terms (i.e. sodium-NT-proBNP and sodium-MAP) in multivariable-adjusted models. This analysis showed that the cross-product term of sodium excretion and NT-proBNP slightly attenuated but remained significant (P interaction =0.009) after simultaneously accounting for MAP and the cross-product term of sodium excretion and MAP. However, the effect modification by MAP (P interaction =0.30) attenuated in the model with simultaneous adjustment for effect modification by NT-proBNP. There was no evidence for an interaction between urinary sodium excretion and sex with risk of CHD (P interaction =0.43). Also, gender did not modify the effect modification by NT-proBNP (P interaction =0.54) or by MAP (P interaction =0.72).
The association between sodium excretion and CHD risk among the hypertensive group was attenuated and no longer significant after accounting for antihypertensive drug use and potential mediators such as urine albumin, eGFR, and plasma NT-proBNP (HR, 1.11; 95% CI, 0.99-1.26; P=0.08). However, the association between 1-g/d increment in sodium excretion and CHD risk among subjects with NT-proBNP levels above the median remained significant (HR, 1.15; 95% CI, 1.02-1.29) even after adjustment for eGFR, SBP, antihypertensive drug use and urinary albumin excretion.
In sensitivity analyses, we repeated the analyses per 1-g/d increment in sodium excretion excluding subjects with potential under or over collections in 24h urine samples or excluding the first 2 years of follow-up. This did not appreciably influence the results (supplemental table).
Results were also similar when we restricted the analyses to subjects with a urinary albumin concentration of >10 mg/L. When we defined CHD as ICD-codes 410 through 414, the HRs with P interaction =0.43). Also, gender did not modify the effect modification by NT-proB oB BNP NP N P interaction =0.54) or by MAP (P interaction =0.72).
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Discussion
In this large prospective population-based study, there was no association between urinary sodium excretion and risk of CHD in the overall cohort. The association between sodium excretion and risk of CHD was modified by NT-proBNP, a marker of myocardial stretch and volume overload. We found positive associations between sodium excretion and risk of CHD among individuals with higher concentrations of NT-proBNP and among individuals with hypertension. Furthermore, the association between sodium excretion and CHD risk among subjects with higher NT-proBNP concentrations seemed to be independent of blood pressure, eGFR, the ratio of total to HDL cholesterol, and urinary albumin excretion at baseline.
Our data suggest that subjects already at higher risk of developing cardiovascular diseases -i.e. subjects with higher NT-proBNP levels or with hypertension -may be prone to the increased risk of CHD associated with high dietary sodium. Indeed, the positive association between sodium intake and CHD risk has generally appeared to be more pronounced in high-risk populations e.g. with higher blood pressure 7, 10 or existing cardiovascular diseases 13 although not consistently 4 and less so in otherwise healthy subjects. 6, 9, 12 However, besides differences in subject characteristics, it cannot be excluded that the inconsistencies between studies for this association may also partially be attributable to differences in assessment of sodium intake, study design including adjustment for confounding variables, or CHD ascertainment and definitions.
The null findings between sodium excretion and CHD risk in the overall cohort or in the among individuals with higher concentrations of NT-proBNP and among individ d dua ua uals ls l w w wit it ith h h hypertension. Furthermore, the association between sodium excretion and CHD risk among u ubj bj bjec ec ects ts ts w w wit it ith h h high gh ghe er er NT-proBNP concentrations s s se see emed to be ind d dep e en en nde de dent n of blood pressure, eG GF FR FR, the rati io o of of of tot otal a a t t to o HD HD HDL L L ch ch ho ol oles es ste e erol, , an n nd u u uri inary ry ry a alb lb bu um min in n e e ex xcr cre e etio on n a at at b bas asel el e in in ine. e.
Ou Our r r da d data ta su ug ugge ge gest st t t tha hat t t su su ubj bj bjec ec ects ts a a alr r rea ea ead d dy a a at t t h h hig g ghe he er r ri ri risk sk sk o of f f de de eve ve elo lo lop pi ping ng g c car ar a di di d ov ov vas as ascu u ula lar r r t t diseases -i.e e. . su su subj bj bjec ec ects ts w w with h h hi hi high gh her er er N N NT-T-pr pr p oB oB oBNP NP NP l le e eve ve v ls ls l o or r r wi wi with th th h h hyp yp yper er rte te tens ns nsio io on n n --ma ma may y y be be be p p prone to the e e by guest on April 20, 2017 http://circ.ahajournals.org/ Downloaded from less susceptible groups do not necessarily imply that excess sodium may have no adverse health consequences in these subjects. A challenge in studying the impact of excess sodium intake in humans is that target-organ damage often develops slowly, likely over many years. 32 Besides, susceptibility to the effects of sodium, such as salt sensitivity, is not limited to hypertensive subjects but is also prevalent among non-hypertensive subjects. 33 Furthermore, blood pressure among normotensive subjects drops after sodium restriction, 15 16 whereas high sodium intake is associated with an increased risk of incident hypertension among initially normotensive subjects. 34 Some of the less susceptible individuals with a higher sodium excretion in our study are likely to develop hypertension or increased NT-proBNP levels, which, in turn, may put them at higher risk of CHD. For developing hypertension, for instance, the residual lifetime risk for middle-aged and elderly American individuals is estimated to be 90%. 35 The effect of sodium excretion on CHD risk among subjects with higher NT-proBNP levels appeared to only be minimally related to other known CHD risk factors such as eGFR and blood pressure. It suggests that also other mechanisms besides kidney function and blood pressure may play a role in the sodium-induced pathogenesis of CHD. Sodium intake is inversely associated with coronary flow reserve, a measure of overall coronary vasodilator capacity and microvascular function. 36 High sodium intake has been positively associated with endothelial dysfunction, 37, 38 resistance to the protective effects of RAAS-blockade (independent of blood pressure) 39, 40 , and increased left ventricular mass. 41 Conversely, sodium reduction has been shown to decrease left ventricular mass 42 and to improve pulse wave velocity 43 and to reduce albuminuria in normotensive 44 and hypertensive subjects 45 , independent of blood pressure.
Several limitations warrant consideration. We only measured sodium excretion and other covariables at baseline. However, because of the prospective design, any misclassification is at higher risk of CHD. For developing hypertension, for instance, the residual lif ifet e etim im me e ri ri r sk sk sk f f for or o middle-aged and elderly American individuals is estimated to be 90%. likely to be random with respect to case status, and therefore would probably underestimate the association between sodium excretion and CHD risk. Second, we performed our analysis in a homogeneous and predominantly white cohort with an unknown proportion of salt sensitive subjects. Results may therefore not be readily generalizable to other populations although we have no reason to believe that the effects of sodium on CHD risk would be less important in other ethnicities. In subjects of African or Asian descent, for instance, blood pressure responses to modifications in sodium intake are generally larger than in white subjects. [46] [47] [48] Third, we did not adjust for multiple comparisons when testing interactions, which may reduce the strength of at least the MAP-by-sodium interaction. The stratified analysis was defined a priori and based on previous observations showing differences in changes in sodium intake on subsequent changes in blood pressure between normotensive and hypertensive subjects. 15, 16 Fourth, the cutoff for NT-proBNP to visualize the interaction was arbitrary and relatively low (e.g. when compared to for instance the diagnostic value of >125 pg/mL used for congestive heart failure for subjects <75 years). Fifth, our data are observational in nature. As with any observational study, unmeasured factors associated with sodium excretion and risk of CHD may introduce residual confounding. For instance, a higher sodium excretion may be a marker for other unhealthy lifestyle choices that we did not measure and therefore could not take into account in our multivariable models such as physical inactivity or lack of fiber intake. On the other hand, we adjusted for numerous important risk factors for CHD including smoking, adiposity and total and HDL cholesterol and also for dietary cations present in fiber-rich food like potassium and magnesium. Last, although there were no univariate cross-sectional associations of sodium excretion with measures of blood pressure, there is a prospective association with incident hypertension in this cohort. 34 on previous observations showing differences in changes in sodium intake on su ub bs bseq eq e ue ue ent nt nt changes in blood pressure between normotensive and hypertensive subjects. 15, 16 Fourth, the cutof ff f fo fo for r r NT NT NT-p -p -pr ro oBN BN NP P P to visualize the interaction w w was as arbitrary and r r re elati tive ve vel ly low (e.g. when co om mp mpared to fo for r in in nst tan an nce e e t t the he he d d di ia iagn gn no os osti ic c v valu u ue of > > >1 125 pg pg pg/m /m mL L L us used ed d f for or co on onge ge ges st stiv ive e e he he hear art t fa fa fai il ilu u ure e e fo or r r su su subj bj bjec ects ts s < < <75 75 ye ea ears rs s) ). F Fif ifth h h, , , ou ou ur r r d d da at ata a ar ar re e e o ob obse se serv rv rvat atio ion n nal l l in in in n nat at atur ur re. e. A A As s wi wi with th a a any ny ny o obs bs bse e erv va vati i ion ona a al r r r tudy, unmea asu su sure re r d d d fa fa f ct ct c or o o s as as asso s s ci ci ciat at a ed ed ed w w wit it i h h h so so sodi di d um um um e exc xc x re re eti ti t on on on a a and nd nd ris s sk k k o o of f f CH CH CHD D ma ma may y y in in intr t oduce k k Strengths of our study are the prospective design, long duration of follow-up, the large number of subjects, elaborate information on subject characteristics including multiple measured blood pressures and medication use, extensive adjustment for potential confounders, and the robustness of the associations in several sensitivity analyses. Another strength is the use of two consecutive 24h urine collections. By repeating the 24h urine collections, we reduced the intraindividual variability. Moreover, the correlation between the two sodium excretions, and thus the repeatability of the sodium assessment, was relatively high, even compared to those reported in previous studies; perhaps due to the shorter time span between the two urine collections in this study compared to the <2 weeks in the other studies.
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Conclusion
In this large population-based cohort of men and women, we found no association between urinary sodium excretion and risk of CHD in the overall cohort. However, the association between sodium excretion and risk of CHD was modified by NT-proBNP. A higher sodium excretion was associated with an increased risk of CHD among subjects with higher levels of NT-proBNP and among subjects with hypertension, both potential indicators of susceptibility to high dietary sodium. Our results are in line with the notion that excess sodium intake is associated with an increased risk of CHD, particularly among vulnerable groups who comprise a large portion of the population.
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